Fructose‐1,6‐bisphosphate reduces inflammatory pain‐like behaviour in mice: role of adenosine acting on A1 receptors
Authors:
Open Access
- 28 August 2009
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 158 (2) , 558-568
Abstract
Background and purpose: D‐Fructose‐1,6‐bisphosphate (FBP) is an intermediate in the glycolytic pathway, exerting pharmacological actions on inflammation by inhibiting cytokine production or interfering with adenosine production. Here, the possible antinociceptive effect of FBP and its mechanism of action in the carrageenin paw inflammation model in mice were addressed, focusing on the two mechanisms described above.Experimental approach: Mechanical hyperalgesia (decrease in the nociceptive threshold) was evaluated by the electronic pressure‐metre test; cytokine levels were measured by elisa and adenosine was determined by high performance liquid chromatography.Key results: Pretreatment of mice with FBP reduced hyperalgesia induced by intraplantar injection of carrageenin (up to 54%), tumour necrosis factor α (40%), interleukin‐1 β (46%), CXCL1 (33%), prostaglandin E2 (41%) or dopamine (55%). However, FBP treatment did not alter carrageenin‐induced cytokine (tumour necrosis factor α and interleukin‐1 β) or chemokine (CXCL1) production. On the other hand, the antinociceptive effect of FBP was prevented by systemic and intraplantar treatment with an adenosine A1 receptor antagonist (8‐cyclopentyl‐1,3‐dipropylxanthine), suggesting that the FBP effect is mediated by peripheral adenosine acting on A1 receptors. Giving FBP to mice increased adenosine levels in plasma, and adenosine treatment of paw inflammation presented a similar antinociceptive mechanism to that of FBP.Conclusions and implications: In addition to anti‐inflammatory action, FBP also presents an antinociceptive effect upon inflammatory hyperalgesia. Its mechanism of action seems dependent on adenosine production but not on modulation of hyperalgesic cytokine/chemokine production. In turn, adenosine acts peripherally on its A1 receptor inhibiting hyperalgesia. FBP may have possible therapeutic applications in reducing inflammatory pain.Keywords
This publication has 62 references indexed in Scilit:
- Anti‐nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1adenosine receptorsBritish Journal of Pharmacology, 2008
- Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory painBritish Journal of Pharmacology, 2008
- IL-33 mediates antigen-induced cutaneous and articular hypernociception in miceProceedings of the National Academy of Sciences, 2008
- Involvement of LTB4 in zymosan-induced joint nociception in mice: participation of neutrophils and PGE2Journal of Leukocyte Biology, 2007
- IL-15 mediates immune inflammatory hypernociception by triggering a sequential release of IFN-γ, endothelin, and prostaglandinProceedings of the National Academy of Sciences, 2006
- Interleukin-18 Induces Mechanical Hypernociception in Rats via Endothelin Acting on ETB Receptors in a Morphine-Sensitive MannerThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Fructose‐1,6‐Diphosphate Suppresses T‐Lymphocyte Proliferation, Promotes Apoptosis and Inhibits Interleukins‐1, 6, β‐Actin mRNAs, and Transcription Factors ExpressionImmunological Investigations, 2004
- Fructose-1,6-diphosphate alone and in combination with cyclosporine potentiates rat cardiac allograft survival and inhibits lymphocyte proliferation and interleukin-2 expression1Transplantation, 2002
- Storage solution containing fructose-1,6-bisphosphate inhibits the excess activation of kupffer cells in cold liver preservation1.Transplantation, 2002
- Effect of exogenous fructose-1,6-bisphosphate on glycolysis in the isolated perfused rat heartAmerican Heart Journal, 1991